Echosens: Launch of the FibroScan®502 Touch

News provided by

Oct 27, 2011, 09:00 ET

PARIS, October 27, 2011 /PRNewswire/ --

Since its initial inception, Echosens has a history of innovation and it continues to widen and strengthen its product range with the recent introduction of the FibroScan^® 502 Touch.

Equipped with a new and more ergonomic tactile interface, and based on patented Vibration-Controlled Transient Elastography (VCTE™), the latest FibroScan^® provides a reliable, accurate and reproducible assessment of liver tissue stiffness.

This patented VCTE technology, developed by Echosens, is unique in measuring liver stiffness at a pre-determined and controlled 50 Hz frequency.

The FibroScan^® 502 Touch offers enhanced patient data management with more complete and personalized exam reports. Compatible with the complete range of FibroScan probes (S+, M+ and XL+) it offers simultaneous connection of 2 probes giving flexibility for the patient assessment. An indicator recommends the probe best suited to the patient's morphology.

Echosens' FS 502 Touch represents a quicker and more complete device built around the latest generation of electronics.

Continuing Echosens' history of innovation, the FS 502 Touch is further enhanced by the optional integration of the latest technological innovation: CAP™ (Controlled Attenuation Parameter), the new parameter for steatosis assessment and quantification.

Echosens has also launched new software for managing FibroScan^® examinations: the Desk Solution. This comprehensive and innovative solution provides ready access to FibroScan assessments on the physician's desk-top PC.

Echosens products are widely available in most global markets and the company is actively pursuing the necessary FDA approvals to homologate its devices for sale in the United States.

About Echosens and Fibroscan^®

FibroScan^® is designed to quantify hepatic elasticity and steatosis in a non-invasive manner in chronic liver diseases assessment.

Founded in 2001, Echosens supplies its products in more than 70 countries through a global network of suppliers. It dedicates a major portion of its activity to research and development in order to invent new medical devices and open up new medical perspectives. The organization works in close cooperation with health professionals and patients' associations to facilitate management and therapeutic monitoring of patients. To date, there around 400 publications which attest to the efficacy of FibroScan in clinical practice.

Press Contact

ECHOSENS
Richard GUILLAUME
[email protected]
+33-144-827850

SOURCE Echosens